StockNews.com started coverage on shares of Kamada (NASDAQ:KMDA – Get Rating) in a research note issued to investors on Saturday. The brokerage issued a buy rating on the biotechnology company’s stock.
Separately, Zacks Investment Research cut shares of Kamada from a buy rating to a hold rating in a research report on Friday, May 6th.
NASDAQ KMDA opened at $4.58 on Friday. The business has a 50 day simple moving average of $5.35 and a two-hundred day simple moving average of $5.87. Kamada has a 1-year low of $4.46 and a 1-year high of $6.96. The stock has a market capitalization of $203.90 million, a PE ratio of -30.53 and a beta of 0.99. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.75 and a quick ratio of 1.16.
A number of institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. grew its stake in shares of Kamada by 151.1% in the first quarter. Goldman Sachs Group Inc. now owns 37,518 shares of the biotechnology company’s stock valued at $208,000 after buying an additional 22,576 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Kamada by 3.1% in the 1st quarter. Vanguard Group Inc. now owns 779,451 shares of the biotechnology company’s stock valued at $4,302,000 after purchasing an additional 23,768 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Kamada by 32.5% in the first quarter. Dimensional Fund Advisors LP now owns 68,889 shares of the biotechnology company’s stock valued at $380,000 after buying an additional 16,886 shares in the last quarter. Acadian Asset Management LLC lifted its stake in Kamada by 7.2% during the first quarter. Acadian Asset Management LLC now owns 877,798 shares of the biotechnology company’s stock worth $4,886,000 after purchasing an additional 58,866 shares during the last quarter. Finally, Citigroup Inc. lifted its position in shares of Kamada by 2,620.0% during the 1st quarter. Citigroup Inc. now owns 36,938 shares of the biotechnology company’s stock worth $206,000 after buying an additional 35,580 shares during the last quarter.
About Kamada (Get Rating)
Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the drug products in Israel, which are manufactured by third parties.
- Get a free copy of the StockNews.com research report on Kamada (KMDA)
- Zoom Video Communications Is Primed To Launch Higher
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Veeva Systems: Increasing NDR and Other Wins
- Institutions Buy The Dip In Petco Health and Wellness Company
- Autozone Edges Past Advanced Auto Parts In Q1 2022
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.